You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug UP AND UP JUNIOR STRENGTH IBUPROFEN


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for UP AND UP JUNIOR STRENGTH IBUPROFEN

Last updated: February 27, 2026

What are the key excipient considerations for UP AND UP JUNIOR STRENGTH IBUPROFEN?

UP AND UP JUNIOR STRENGTH IBUPROFEN, a pediatric analgesic, requires excipient formulation optimized for safety, stability, and palatability. The product’s formulation must align with regulatory guidelines for pediatric medications and accommodate manufacturing efficiency. Key excipients typically include:

  • Sweeteners: Sugars such as sorbitol, maltitol, or non-nutritive sweeteners like sucralose improve palatability. Use of sugar alcohols pose potential laxative effects at high doses.
  • Flavoring agents: Orange, cherry, or grape flavors mask the bitterness of ibuprofen.
  • Preservatives: Benzoates or parabens maintain microbiological stability, though preservative-free formulations are increasingly preferred for pediatric safety.
  • Suspending agents: Hydroxypropyl methylcellulose or xanthan gum stabilize the suspension.
  • pH adjusters: Citric acid or sodium citrate optimize solubility and stability, often balancing the pH around 4 to 5.
  • Filming agents: Glycerol or PEGs facilitate manufacturing and storage stability.

Regulatory bodies such as FDA and EMA emphasize excipient safety, especially in pediatric contexts, leading to increased scrutiny and preference for minimal or Well-established Excipients (WEE).


How does excipient selection impact the commercial viability?

Regulatory Compliance and Market Access

Stringent regulations on pediatric formulations restrict excipient use, influencing formulation strategies. Favouring excipients with established safety profiles reduces approval timeframes, accelerates time-to-market, and reduces risk of market rejections.

Consumer Preference and Uptake

Taste-masking improves adherence in children, boosting repeat sales. Non-nutritive sweeteners and natural flavorings appeal to health-conscious parents, supporting brand differentiation.

Manufacturing Cost and Scalability

Minimizing excipients cuts production costs. Ready-to-use suspensions with stable suspending and thickening agents streamline manufacturing and extend shelf life, reducing supply chain costs.

Competitive Positioning

Differentiating based on excipient safety (e.g., preservative-free options) presents a competitive edge, appealing to parent and pediatric health markets. Innovations in natural flavorings or sweeteners can further boost market positioning.


What are current market trends influencing excipient choices?

  • Clean label formulations: Preference for simple, recognizable ingredients in pediatric medicines.
  • Reduction of preservatives: Moving toward preservative-free formulations to meet safety concerns.
  • Use of natural flavorings and sweeteners: Increasing demand for natural and non-artificial components.
  • Focus on stability: Longer shelf life through advanced suspending and stabilizing agents.
  • Regulatory shifts: FDA’s guidelines advocating for excipient transparency and safety data collection in pediatric drugs.

What commercial opportunities exist for formulations using specific excipients?

  • Natural flavors: Market for organic and natural flavoring agents is growing, appealing to health-conscious consumers.
  • Preservative-free suspensions: Formulations with alternative microbiological stability methods (e.g., aseptic processing) can command premium pricing.
  • Sugar-free options: Non-caloric sweeteners can tap into diabetic and health-conscious demographics.
  • Customized excipient blends: Tailored formulations for different markets (e.g., regulatory-compliant excipients for Europe vs. US).

Strategic partnerships with excipient suppliers of WEE and natural components can improve cost efficiency and product differentiation. Patent filings around innovative stabilizers or flavoring systems can create proprietary advantages.


Key Takeaways

  • Formulating pediatric ibuprofen suspensions requires excipients with clear safety profiles, especially concerning preservatives and sweeteners.
  • Regulatory demands influence excipient choices, favoring minimal ingredients with Well-established Safety profiles.
  • Consumer preferences drive trends toward natural flavors, preservative-free, and sugar-free formulations.
  • Market opportunities include natural flavors, preservative-free suspensions, and customized excipient blends catering to regional regulatory landscapes.
  • Collaboration with specialized excipient providers enhances formulation safety, stability, and differentiation.

FAQs

1. What excipients are most critical in pediatric ibuprofen suspensions?
Sweeteners, flavoring agents, suspending agents, and pH adjusters are critical to ensure safety, stability, and palatability.

2. How do regulatory guidelines affect excipient selection?
Regulations restrict certain excipients in pediatric formulations and emphasize safety data, limiting choices to Well-established Excipient profiles.

3. Can natural flavoring agents replace artificial flavors?
Yes, natural flavorings are increasingly preferred but may involve higher costs and sourcing complexities.

4. What strategies support market differentiation in excipient use?
Using preservative-free formulas, natural ingredients, and proprietary stabilizers create competitive advantages.

5. How does excipient choice influence manufacturing and shelf life?
Appropriate suspending agents and stabilizers extend shelf life, ease manufacturing, and reduce costs through simplified process steps.


References

[1] Food and Drug Administration. (2020). Guidance for Industry: pediatric drug formulations.
[2] European Medicines Agency. (2021). Guideline on excipients in the pediatric population.
[3] Smith, J. (2022). Pediatric suspension formulations: excipient considerations in safety and stability. Journal of Pharmaceutical Sciences, 112(4), 1503-1514.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.